The role of lncRNA NEAT1 in human cancer chemoresistance.

IF 5.3 2区医学 Q1 ONCOLOGY Cancer Cell International Pub Date : 2024-07-05 DOI:10.1186/s12935-024-03426-x

Feng Long, Xue Li, Jingyu Pan, Hailin Ye, Cuixia Di, Yong Huang, Jiawei Li, Xuan Zhou, Huiyi Yi, Qiaozhen Huang, Jing Si

{"title":"The role of lncRNA NEAT1 in human cancer chemoresistance.","authors":"Feng Long, Xue Li, Jingyu Pan, Hailin Ye, Cuixia Di, Yong Huang, Jiawei Li, Xuan Zhou, Huiyi Yi, Qiaozhen Huang, Jing Si","doi":"10.1186/s12935-024-03426-x","DOIUrl":null,"url":null,"abstract":"<p><p>Chemotherapy is currently one of the most effective methods in clinical cancer treatment. However, chemotherapy resistance is an important reason for poor chemotherapy efficacy and prognosis, which has become an urgent problem to be solved in the field of cancer chemotherapy. Therefore, it is very important to deeply study and analyze the mechanism of cancer chemotherapy resistance and its regulatory factors. Long non-coding RNA nuclear paraspeckle assembly transcript 1 (LncRNA NEAT1) has been shown to be closely associated with chemotherapy resistance in cancer. NEAT1 induces cancer cell resistance to chemotherapeutic drugs by regulating cell apoptosis, cell cycle, drug transport and metabolism, DNA damage repair, EMT, autophagy, cancer stem cell characteristics, and metabolic reprogramming. This indicates that NEAT1 may be an important target to overcome chemotherapy resistance and is expected to be a potential biomarker to predict the effect of chemotherapy. This article summarizes the expression characteristics and clinical characteristics of NEAT1 in different cancers, and deeply discusses the regulatory role of NEAT1 in cancer chemotherapy resistance and related molecular mechanisms, aiming to clarify NEAT1 as a new target to overcome cancer chemotherapy resistance and the feasibility of chemotherapy sensitizers, with a view to providing a potential therapeutic direction for overcoming the dilemma of cancer resistance in the future.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227196/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-024-03426-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Chemotherapy is currently one of the most effective methods in clinical cancer treatment. However, chemotherapy resistance is an important reason for poor chemotherapy efficacy and prognosis, which has become an urgent problem to be solved in the field of cancer chemotherapy. Therefore, it is very important to deeply study and analyze the mechanism of cancer chemotherapy resistance and its regulatory factors. Long non-coding RNA nuclear paraspeckle assembly transcript 1 (LncRNA NEAT1) has been shown to be closely associated with chemotherapy resistance in cancer. NEAT1 induces cancer cell resistance to chemotherapeutic drugs by regulating cell apoptosis, cell cycle, drug transport and metabolism, DNA damage repair, EMT, autophagy, cancer stem cell characteristics, and metabolic reprogramming. This indicates that NEAT1 may be an important target to overcome chemotherapy resistance and is expected to be a potential biomarker to predict the effect of chemotherapy. This article summarizes the expression characteristics and clinical characteristics of NEAT1 in different cancers, and deeply discusses the regulatory role of NEAT1 in cancer chemotherapy resistance and related molecular mechanisms, aiming to clarify NEAT1 as a new target to overcome cancer chemotherapy resistance and the feasibility of chemotherapy sensitizers, with a view to providing a potential therapeutic direction for overcoming the dilemma of cancer resistance in the future.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

lncRNA NEAT1 在人类癌症化疗耐药性中的作用

化疗是目前临床治疗癌症最有效的方法之一。然而，化疗耐药是导致化疗疗效和预后不佳的重要原因，已成为肿瘤化疗领域亟待解决的问题。因此，深入研究和分析癌症化疗耐药的机制及其调控因素具有十分重要的意义。研究表明，长非编码RNA核旁组装转录本1（LncRNA NEAT1）与癌症化疗耐药密切相关。NEAT1 通过调控细胞凋亡、细胞周期、药物转运和代谢、DNA 损伤修复、EMT、自噬、癌症干细胞特征和代谢重编程，诱导癌细胞对化疗药物产生耐药性。这表明 NEAT1 可能是克服化疗耐药性的重要靶点，并有望成为预测化疗效果的潜在生物标志物。本文总结了NEAT1在不同癌症中的表达特点和临床特征，深入探讨了NEAT1在癌症化疗耐药中的调控作用及相关分子机制，旨在阐明NEAT1作为克服癌症化疗耐药的新靶点及化疗增敏剂的可行性，以期为未来克服癌症耐药困境提供一个潜在的治疗方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Cell International ONCOLOGY-

CiteScore

10.90

自引率

1.70%

发文量

360

审稿时长

1 months

期刊介绍： Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.